Related Experiment Video
Updated: Jun 12, 2026
Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria
Published on: November 10, 2015
Prevalence of Plasmodium falciparum Drug Resistance Markers pfcrt K76T and pfaat1 S258L in Southern Rwanda, 2010 to
Emma Schallenberg1, Welmoed van Loon1, Djibril Mbarushimana2
1Institute of International Health, Charité Center for Global Health, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Background:
In many countries in Sub-Saharan Africa, the Plasmodium falciparum chloroquine resistance marker pfcrt K76T disappeared within a decade after use of chloroquine ceased. pfaat1 S258L has recently been implicated as another chloroquine resistance marker. Both genes may affect parasite susceptibility to partner drugs in artemisinin-based combination therapy. Rwanda abolished chloroquine use in 2001, and since 2006 the first-line antimalarial is artemether-lumefantrine. However, partial artemisinin resistance emerged in the region. We assessed the prevalence of pfcrt and pfaat1 markers in Huye district between 2010 and 2023, following trends and updating the status in southern Rwanda.
Methods:
P. falciparum-positive blood samples from community children and malaria patients collected in 2010, 2014, 2018, 2019, and 2023 were examined. pfcrt K76T was genotyped by restriction fragment length polymorphism, and pfaat1 S258L by high-resolution melting curve (2010-2019). Samples from 2023 were subjected to nanopore sequencing.
Results:
In 606 samples, pfcrt K76T prevalence declined from 76% (95% confidence interval [CI], 68%-83%) to 18% (95% CI, 11%-25%) between 2010 and 2018 but remained constant since at around 25% (P < .001). No other pfcrt markers were observed. pfaat1 S258L has remained at or near fixation. The artemisinin resistance marker pfk13 R561H was associated with pfcrt K76T (P = .02).
Discussion:
The persistence of pfcrt K76T 20 years after abolishing chloroquine use indicates ongoing drug selection or importation. The fixation of pfaat1 S258L argues against a major fitness cost of this variant in Huye. Increases in partial artemisinin resistance in Rwanda and molecular markers indicate compromised lumefantrine efficacy. The observed pfcrt and pfaat1 signatures in the study area might be of use in guiding artemisinin partner drug alternatives.
